These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 4070298)
1. Generic Pharmaceutical Industry Association Orphan Drug Institute. Haddad W Prog Clin Biol Res; 1985; 197():41-5. PubMed ID: 4070298 [No Abstract] [Full Text] [Related]
3. Orphan Drug Act on congressional agenda. von Oehsen WH Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123 [TBL] [Abstract][Full Text] [Related]
4. The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development. Engstrom LO Prog Clin Biol Res; 1985; 197():25-30. PubMed ID: 4070295 [No Abstract] [Full Text] [Related]
5. Orphan products development and some methods for maximizing the usefulness of research on rare diseases. Finkel MJ Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285 [No Abstract] [Full Text] [Related]
6. Should the patent system for new medicines be abolished? DiMasi JA; Grabowski HG Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100 [No Abstract] [Full Text] [Related]
7. The development of orphan drugs--a pharmaceutical company perspective. Stucki JC Prog Clin Biol Res; 1985; 197():95-104. PubMed ID: 4070303 [No Abstract] [Full Text] [Related]
8. The fuel to run the orphan drug engine: a medical school-based Orphan Disease Center Program. Brewer GJ Prog Clin Biol Res; 1985; 197():123-38. PubMed ID: 4070287 [No Abstract] [Full Text] [Related]
9. Academic center approaches to orphan drug research and development. Hauck FP; Chung EY; Van Woert MH Prog Clin Biol Res; 1985; 197():115-22. PubMed ID: 4070286 [No Abstract] [Full Text] [Related]
10. Orphan drug development in the United States. Groft SC CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306 [TBL] [Abstract][Full Text] [Related]
13. Orphan drug development for the treatment of rare chronic diseases. Moore ES Tex Hosp; 1988 Jul; 44(2):20-1. PubMed ID: 10288218 [No Abstract] [Full Text] [Related]
14. Are orphan product program funds underused by nuclear medicine researchers? Harby K J Nucl Med; 1988 Jun; 29(6):1011-2. PubMed ID: 3373310 [No Abstract] [Full Text] [Related]
15. The role of voluntary disease organizations in research and development of orphan drugs. Horansky R Prog Clin Biol Res; 1985; 197():179-81. PubMed ID: 4070293 [No Abstract] [Full Text] [Related]
16. The Pharmaceutical Manufacturers Association Commission on Drugs for Rare Diseases. Goldstein GS Prog Clin Biol Res; 1985; 197():35-9. PubMed ID: 4070297 [No Abstract] [Full Text] [Related]
17. [Orphan drugs]. Galeffi C Ann Ist Super Sanita; 1991; 27(2):341-3. PubMed ID: 1661568 [TBL] [Abstract][Full Text] [Related]
18. When drugs are in short supply. Zurlinden J Nurs Spectr (Wash D C); 1999 Feb; 9(4):15-6. PubMed ID: 10542818 [No Abstract] [Full Text] [Related]
19. Drug development and patent law. Nusbaum NJ N Y State J Med; 1992 Mar; 92(3):86-7. PubMed ID: 1557205 [No Abstract] [Full Text] [Related]
20. Drug legislation. Drug companies divided. Gershon D Nature; 1990 May; 345(6270):6. PubMed ID: 2330052 [No Abstract] [Full Text] [Related] [Next] [New Search]